234082-33-8

Basic information

• Product Name: tert-Butyl 4-(4-(ethoxycarbonyl)phenyl)piperazine-1-carboxylate
• Synonyms: tert-Butyl 4-(4-(ethoxycarbonyl)phenyl)piperazine-1-carboxylate;Ethyl 4-(4-BOC-piperazino)benzoate
• CAS NO: 234082-33-8
• Molecular Formula: C₁₈H₂₆N₂O₄
• Molecular Weight: 334.41004
• Mol File: 234082-33-8.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 463.7±40.0 °C(Predicted)
• Appearance: /
• Density: 1.136±0.06 g/cm3(Predicted)
• PKA: 2.47±0.10(Predicted)
• CAS DataBase Reference: tert-Butyl 4-(4-(ethoxycarbonyl)phenyl)piperazine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butyl 4-(4-(ethoxycarbonyl)phenyl)piperazine-1-carboxylate(234082-33-8)
• EPA Substance Registry System: tert-Butyl 4-(4-(ethoxycarbonyl)phenyl)piperazine-1-carboxylate(234082-33-8)

Safety Data

• Hazardous Substances Data: 234082-33-8(Hazardous Substances Data)

Usage

General Description

Tert-butyl 4-(4-(ethoxycarbonyl)phenyl)piperazine-1-carboxylate is a chemical compound with the molecular formula C21H32N2O4. It is a piperazine derivative with a tert-butyl group, an ethoxycarbonyl group, and a phenyl group. tert-Butyl 4-(4-(ethoxycarbonyl)phenyl)piperazine-1-carboxylate is commonly used in medicinal chemistry and pharmaceutical research as a building block for the synthesis of various bioactive molecules and drug candidates. It has been studied for its potential pharmacological properties, particularly in the context of central nervous system disorders and related therapeutic interventions. As a piperazine derivative, it may exhibit affinity for certain receptor targets and biological pathways, making it of interest for drug discovery and development efforts.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 80518-57-6 ethyl 4-(piperazin-1-yl)benzoate 
• 451-46-7 4-fluorobenzoic acid ethyl ester 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 123-91-1 1,4-dioxane 
• 5798-75-4 Ethyl 4-bromobenzoate 
• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 

Downstream Products

• 162046-66-4 4-(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)benzoic acid 
• 406233-75-8 3-nitro-4-((2-(phenylthio)ethyl)amino)-N-(4-piperazin-1-ylbenzoyl)benzenesulfonamide 
• 406231-38-7 4-{4-[3-nitro-4-(2-phenylsulfanyl-ethylamino)-benzenesulfonylaminocarbonyl]-phenyl}-piperazine-1-carboxylic acid tert-butyl ester 
• 163210-45-5 4-[4-(2-benzenesulfonylamino-2-tert-butoxycarbonyl-ethylcarbamoyl)-phenyl]-piperazine-1-carboxylic acid tert-butyl ester 
• 163209-37-8 (S)-2-Benzenesulfonylamino-3-(4-piperazin-1-yl-benzoylamino)-propionic acid 
• 80518-57-6 ethyl 4-(piperazin-1-yl)benzoate 
• 1374882-66-2 {(S)-1-[(S)-2-(4-{4'-[4-(4-cyclopropanecarbonyl-piperazin-1-yl)-benzoylamino]-biphenyl-4-yl}-1H-imidazol-2-yl)-pyrrolidine-1-carbonyl]-2-methyl-propyl}-carbamic acid methyl ester 
• 1018631-34-9 4-(4-cyclopropanecarbonyl-piperazin-1-yl)-benzoic acid 
• 1374891-49-2 N-(4-bromo-phenyl)-4-(4-cyclopropanecarbonyl-piperazin-1-yl)-benzamide 
• 1374891-52-7 (S)-2-(4-{4'-[4-(4-Cyclopropanecarbonyl-piperazin-1-yl)-benzoylamino]-biphenyl-4-yl}-1H-imidazol-2-yl)-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1374882-70-8 4-[4-(4'-{2-[(S)-1-((S)-2-Methoxycarbonylamino-3-methyl-butyryl)-pyrrolidin-2-yl]-1H-imidazol-4-yl}-biphenyl-4-ylcarbamoyl)-phenyl]-piperazine-1-carboxylic acid tert-butyl ester 
• 85474-75-5 4-(piperazin-1-yl)benzoic acid 

Relevant articles and documents

Electrochemical Cross-Dehydrogenative Aromatization Protocol for the Synthesis of Aromatic Amines

The introduction of amines onto aromatics without metal catalysts and chemical oxidants is synthetically challenging. Herein, we report the first example of an electrochemical cross-dehydrogenative aromatization (ECDA) reaction of saturated cyclohexanones and amines to construct anilines without additional metal catalysts and chemical oxidants. This reaction exhibits a broad scope of cyclohexanones including heterocyclic ketones, affording a variety of aromatic amines with various functionalities, and shows great potential in the synthesis of biologically active compounds.

Protein degradation targeting chimera for degrading androgen receptor

The invention relates to a novel difunctional molecule compound based on VHL ligand induction and application of the difunctional molecule compound in synthesis of the compounds and pharmaceutical compositions thereof. The compound is shown as a formula I. The compound can selectively induce AR protein degradation and can be used for treating cancers such as prostatic cancer and breast cancer.

Design and characterization of cereblon-mediated androgen receptor proteolysis-targeting chimeras

Proteolysis-targeting chimera (PROTAC)-mediated protein degradation is a rapidly emerging therapeutic intervention that induces the degradation of targeted proteins. Herein, we report the design and biological evaluation of a series of androgen receptor (AR) PROTAC degraders for the treatment of metastatic castration-resistant prostate cancer. Predominantly, instead of thalidomide, we utilized the TD-106 scaffold, a novel cereblon (CRBN) binder that was identified in our previous study. Our results suggest that the linker position in the TD-106 CRBN binder is critical for the efficiency of AR degradation. The compounds attached to the 6-position of TD-106 promoted better degradation of AR than those at the 5- and 7-positions. Among the synthesized AR PROTACs, the representative degrader 33c (TD-802) effectively induced AR protein degradation, with a degradation concentration 50% of 12.5 nM and a maximum degradation of 93% in LNCaP prostate cancer cells. Additionally, most AR PROTAC degraders, including TD-802, displayed good liver microsomal stability and in vivo pharmacokinetic properties. Finally, we showed that TD-802 effectively inhibited tumor growth in an in vivo xenograft study.